Cargando…
The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
The immune checkpoint programmed cell death protein 1 (PD-1) plays a major role in T cell exhaustion in cancer and chronic HIV infection. The inhibitor of apoptosis protein antagonist Debio 1143 (D1143) enhances tumor cell death and synergizes with anti-PD-1 agents to promote tumor immunity and disp...
Autores principales: | Bobardt, Michael, Kuo, Joseph, Chatterji, Udayan, Wiedemann, Norbert, Vuagniaux, Gregoire, Gallay, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980394/ https://www.ncbi.nlm.nih.gov/pubmed/31978106 http://dx.doi.org/10.1371/journal.pone.0227715 |
Ejemplares similares
-
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019) -
DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death
por: Thibault, Benoît, et al.
Publicado: (2018) -
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
por: Langdon, Casey G., et al.
Publicado: (2015) -
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
por: Bellaye, Pierre-Simon, et al.
Publicado: (2018) -
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
por: Gomez‐Roca, Carlos, et al.
Publicado: (2021)